A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Residual Disease
Interventions: DRUG: Tetrathiomolybdate|DRUG: Capecitabine|DRUG: Pembrolizumab
Sponsor: Dartmouth-Hitchcock Medical Center